EFFECT OF DAPAGLIFLOZIN ON BODY COMPOSITION IN PATIENTS WITH TYPE 1 DIABETES


Por: Sierra, N, Leon, J, Del Valle, C, Exposito, J, Villena, B, Morant, C, Izquierdo, E and Arino, C

Publicada: 1 jun 2021
Resumen:


Filiaciones:
:
 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain

:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

:
 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain

:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

:
 Fdn Promot Hlth & Biomed Res Valencian Reg FISABI, Endocrinol, Valencia, Spain

:
 Univ Valencia, Dept Med, Valencia, Spain

 Hosp Univ Doctor Peset, Endocrinol, Valencia, Spain

:
 Doctor Peset Univ Hosp, Endocrinol & Nutr, Valencia, Spain

 Univ Valencia, Dept Med, Valencia, Spain
ISSN: 15209156





DIABETES TECHNOLOGY & THERAPEUTICS
Editorial
Mary Ann Liebert Inc., 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 23 Número:
Páginas: 167-168
WOS Id: 000656638700419

MÉTRICAS